NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B

Description

National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 moths. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points. Lot 18: Lot 18 - Fresh Frozen Plasma Fresh Frozen Plasma Lot 16: Lot 16 - Prothrombin Complex dried Prothrombin Complex dried Lot 15: Lot 15 - Fibrinogen Concentrate Fibrinogen Concentrate Lot 14: Lot 14 - Von willebrands factor - Recombinant Von willebrands factor - Recombinant Lot 17: Lot 17 - Protein C Concentrate Protein C Concentrate Lot 10: Lot 10 - Factor XIII - Plasma Derived Factor XIII - Plasma Derived Lot 11: Lot 11 - Factor XIII - Recombinant Factor XIII - Recombinant Lot 9: Lot 9 - Factor X Factor X Lot 8: Lot 8 - Factor IX - High Purity Factor IX Factor IX - High Purity Factor IX Lot 7: Lot 7 - Factor VIII Inhibitor Bypassing Fraction Factor VIII Inhibitor Bypassing Fraction Lot 13: Lot 13 - Von willebrands factor - Plasma Derived Von willebrands factor - Plasma Derived Lot 12: Lot 12 - Factor VIII/ von willebrands factor Factor VIII/ von willebrands factor Lot 6: Lot 6 - Porcine Factor VIII - susoctocog alfa Porcine Factor VIII - susoctocog alfa Lot 5: Lot 5 - Recombinant Factor VII Recombinant Factor VII Lot 4: Lot 4 - rFIX - Standard Half Life rFIX - Standard Half Life Lot 3: Lot 3 - nonacog beta pegol (rFIX EHL) nonacog beta pegol (rFIX EHL) Lot 2: Lot 2 - albutrepenonacog alfa (rFIX EHL) albutrepenonacog alfa (rFIX EHL) Lot 1: Lot 1 - eftrenonacog alfa (rFIX EHL) eftrenonacog alfa (rFIX EHL)